RespireRx Pharmaceuticals Inc. is dedicated to researching, developing, and commercializing pharmaceutical products aimed at addressing neurological and psychiatric conditions. The company operates through two primary therapeutic platforms: ResolutionRx, which investigates pharmaceutical cannabinoids, and EndeavourRx, focused on neuromodulators. The ResolutionRx platform encompasses cannabinoids such as dronabinol, a compound that interacts with CB1 and CB2 endocannabinoid receptors.